Normalization of Tumor Microenvironment by Neem Leaf Glycoprotein Potentiates Effector T Cell Functions and Therapeutically Intervenes in the Growth of Mouse Sarcoma

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Barik, Subhasis ^a   Banerjee, Saptak ^a   Mallick, Atanu ^a   Goswami, Kuntal Kanti ^a   Roy, Soumyabrata ^a   Bose, Anamika ^b   Baral, Rathindranath ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b BOSE INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN; GRANZYME B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 10; INTERLEUKIN 6; PERFORIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AZADIRACHTA INDICA; CANCER GROWTH; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DENSITOMETRY; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; IMMUNOBLOTTING; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PLANT LEAF; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; PURIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION;

ANIMALS; ANOXIA; ANTIGENS, CD95; APOPTOSIS; AZADIRACHTA; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FAS LIGAND PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; LYMPHOCYTE DEPLETION; MICE; NEOVASCULARIZATION, PATHOLOGIC; PLANT LEAVES; SARCOMA; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

AZADIRACHTA INDICA; MURINAE; MUS;

EID: 84879062648     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066501     Document Type: Article

References (41)

1. Lorusso G, Rüegg C, (2008) The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 130: 1091-1103.
2. Prager GW, Poettler M, Unseld M, Zielinski CC, (2012) Angiogenesis in cancer: Anti-VEGF escapes mechanisms. Transl Lung Cancer Res 1: 14-25.
3. Witz IP, (2009) The tumor-microenvironment interactions: The making of a paradigm. Cancer Microenviron 2: 9-17.
4. Egeblad M, Nakasone ES, Werb Z, (2010) Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 18: 884-901.
5. Rehman J, Li J, Orscell C, March K, (2003) Peripheral blood endothelial cells are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107: 1164-1169.
6. Bhowmick NA, Neilson EG, Moses HL, (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432: 332-337.
7. Whiteside TL, (2006) Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16: 3-15.
8. Mbeunkui F, Johann DJ Jr, (2009) Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 63: 571-582.
9. Biswas K, Chattopadhyay I, Banerjee RK, Bandopadhyay U, (2002) Biological activities and medicinal properties of neem (Azadirachta indica). Curr Sci 82: 1336-1345.
10. Paul R, Prasad M, Sah NK, (2011) Anticancer biology of Azadirachta indica L (neem) A mini review. Cancer Biol Ther 12: 467-476.
11. Fujiwara T, Takeda T, Ogihara Y, Shimizu M, Nomura T, et al. (1982) Studies on the structure of polysaccharides from the bark of Melia azadirachta. Chem Pharm Bull 30: 4025-4030.
12. Baral R, Chattopadhyay U, (2004) Neem (Azadirachta indica) leaf mediated immune activation causes prophylactic growth inhibition of murine Ehrlich carcinoma and B16 melanoma. Int Immunopharmacol 4: 355-366.
13. Baral R, Mandal I, Chattopadhyay U, (2005) Immunostimulatory neem leaf preparation acts as an adjuvant to enhance the efficacy of poorly immunogenic B16 melanoma surface antigen vaccine. Int Immunopharmacol 5: 1343-1352.
14. Chakraborty K, Bose A, Pal S, Sarkar K, Goswami S, et al. (2008) Neem leaf glycoprotein restores the impaired chemotactic activity of peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients by maintaining CXCR3/CXCL10 balance. Int Immunopharmacol 8: 330-340.
15. Mallick A, Ghosh S, Banerjee S, Majumder S, Das A, et al. (2013) Neem leaf glycoprotein is nontoxic to physiological functions of Swiss mice and Sprague Dawley rats: histological, biochemical and immunological perspectives. Int Immunopharmacol 15: 73-83.
16. Bose A, Chakraborty K, Sarkar K, Goswami S, Chakraborty T, et al. (2009) Neem leaf glycoprotein induces perforin mediated tumor cell killing by T and NK cells through differential regulation of IFNγ signaling. J Immunother 32: 42-53.
17. Goswami S, Bose A, Sarkar K, Roy S, Chakraborty T, et al. (2010) Neem leaf glycoprotein matures myeloid derived dendritic cells and optimizes anti-tumor T cell functions. Vaccine 28: 1241-1252.
18. Haque E, Baral R, (2006) Neem (Azadirachta indica) leaf preparation induces prophylactic growth inhibition of murine Ehrlich carcinoma in Swiss and C57BL/6 by activation of NK cells and NK-T cells. Immunobiology 211: 721-731.
19. Chakraborty T, Bose A, Barik S, Goswami KK, Banerjee S, et al. (2011) Neem leaf glycoprotein inhibits CD4+CD25+Foxp3+ Tregs to restrict murine tumor growth. Immunotherapy 3: 949-969.
20. Bose A, Chakraborty K, Sarkar K, Goswami S, Haque E, et al. (2009) Neem leaf glycoprotein directs T-bet associated type 1 immune commitment. Human Immunol 70: 6-15.
21. Sarkar K, Bose A, Haque E, Chakraborty K, Chakraborty T, et al. (2009) Induction of type 1 cytokines during neem leaf glycoprotein assisted carcinoembryonic antigen vaccination is associated with nitric oxide production. Int Immunopharmacol 9: 753-760.
22. Chakraborty K, Bose A, Chakraborty T, Sarkar K, Goswami S, et al. (2010) Restoration of dysregulated CC chemokine signaling for monocyte/macrophage chemotaxis in head and neck squamous cell carcinoma patients by neem leaf glycoprotein maximizes tumor cell cytotoxicity. Cell Mol Immunol 7: 396-408.
23. Sarkar K, Bose A, Chakraborty K, Haque E, Ghosh D, et al. (2008) Neem leaf glycoprotein helps to generate carcinoembryonic antigen specific anti-tumor immune responses utilizing macrophage-mediated antigen presentation. Vaccine 26: 4352-4362.
24. Sarkar K, Goswami S, Roy S, Mallick A, Chakraborty K, et al. (2010) Neem leaf glycoprotein enhances carcinoembryonic antigen presentation of dendritic cells to T and B cells for induction of antitumor immunity by allowing generation of immune effector/memory response. Int Immunopharmacol 10: 865-887.
25. Mallick A, Barik S, Goswami KK, Banerjee S, Ghosh S, et al. (2013) Neem leaf glycoprotein activates CD8+ T cells to promote therapeutic anti-tumor immunity inhibiting the growth of mouse sarcoma. PLoS ONE 8: e47434.
26. Zamarron BF, Chen W, (2011) Dual Roles of Immune Cells and Their Factors in Cancer Development and Progression. Int J Biol Sci 7: 651-658.
27. Hinrichs C, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, et al. (2008) IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111: 5326-5333.
28. Ebert LM, Schaerli P, Moser B, (2005) Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Mol Immunol 42: 799-809.
29. Lu B, Finn OJ, (2008) T-cell death and cancer immune tolerance. Cell Death Differ 15: 70-79.
30. Zheng Y, Zha Y, Gajewski TF, (2008) Molecular regulation of T-cell anergy. EMBO ep 9: 50-55.
31. Wood KJ, Sakaguchi S, (2003) Regulatory T cells in transplantation tolerance. Nat Rev Immunol 3: 199-210.
32. Murdoch C, Muthana M, Coffelt SB, Lewis CE, (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8: 618-663.
33. Kerbel RS, (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13: 31-36.
34. Xu L, Xu W, Qiu S, Xiong S, (2010) Enrichment of CCR6(+)Foxp3(+) regulatory T cells in the tumour mass correlates with impaired CD8(+) T cell function and poor prognosis of breast cancer. Clin Immunol 135: 466-475.
35. Stadler WM, Kuzel T, Dumas M, Vogelzang NJ, (1998) Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol 16: 1820-1825.
36. Rosenberg SA, Spiess P, Lafreniere R, (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321.
37. Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, et al. (2003) Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 89: 1172-1179.
38. Yu J, Tian R, Xiu B, Yan J, Jia R, et al. (2009) Antitumor activity of T cells generated from lymph nodes draining the SEA-expressing murine B16 melanoma and secondarily activated with dendritic cells. Int J Biol Sci 5: 135-146.
39. Bailey JL (1967) Miscellaneous analytical methods. In: Bailey JL, editor. Techniques in Protein Chemistry. New York: Elsevier Science Publishing 340-346.
40. Hayashi RJ, Loh DY, Kanagawa O, Wang F, (1998) Differences between responses of naive and activated T cells to anergy induction. J Immunol 160: 33-38.
41. Komita H, Zhao X, Taylor JL, Sparvero LJ, Amoscato AA, et al. (2008) CD8+ T-cell responses against hemoglobin-b prevent solid tumor growth. Cancer Res 68: 8076-8084.